‘Mitotherapy’ for heart failure

Simple item page
dc.contributor.authorSanchís-Gomar, Fabián
dc.contributor.authorLippi, Giuseppe
dc.contributor.authorLucía Mulas, Alejandro
dc.date.accessioned2016-05-19T08:10:45Z
dc.date.available2016-05-19T08:10:45Z
dc.date.issued2016
dc.description.abstractAbnormalities in mitochondrial dynamics along with those for the molecular mediators involved are presently being viewed with increased interest in the field of cardiovascular disease. Recent research highlights OPA1, a dynamin-like GTPase mediating mitochondrial fusion, as well as the 'mitoproteases' OMA1 and YME1L, as potential therapeutic targets against heart failure.spa
dc.description.filiationUEMspa
dc.description.impact10.732 JCR (2016) Q1, 12/290 Biochemistry and Molecular Biology, 14/190 Cell Biology, 6/128 Medicine, Research and Experimentalspa
dc.description.impact5.052 SJR (2016) Q1, 25/423 Molecular Biology, 6/183 Molecular Medicinespa
dc.description.impactNo data IDR 2016spa
dc.description.sponsorshipSin financiaciónspa
dc.identifier.citationSanchis-Gomar, F., Lippi, G., & Lucia, A. (2016). ‘Mitotherapy’ for heart failure. Trends in molecular medicine, 22(4), 267-269.spa
dc.identifier.doi10.1016/j.molmed.2016.02.007
dc.identifier.issn14714914
dc.identifier.issn1471499X
dc.identifier.urihttp://hdl.handle.net/11268/5149
dc.language.isoengspa
dc.peerreviewedSispa
dc.rights.accessRightsrestricted accessspa
dc.subject.uemCorazónspa
dc.subject.uemEnvejecimientospa
dc.subject.unescoEnfermedad cardiovascularspa
dc.subject.unescoEnvejecimientospa
dc.title‘Mitotherapy’ for heart failurespa
dc.typejournal articlespa
dspace.entity.typePublication
relation.isAuthorOfPublicationd3691359-d7bd-4a12-b84e-338e28c81f9f
relation.isAuthorOfPublication.latestForDiscoveryd3691359-d7bd-4a12-b84e-338e28c81f9f

Files

Collections

Área de Actividad Física y Salud